Track topics on Twitter Track topics that are important to you
London, UK, 1st August 2018 / Sciad Newswire / ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory Syncytial Virus (RSV), today announced the ...
The CMO appointment has been made as the company prepares its lead RSV candidate to enter phase II of clinical trials
Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended) ...
Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research (ICAR) ReViral Ltd.,...
ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced the appointment of Seth Het...
Proven leader with extensive corporate strategy experience in the biotechnology sector Dr. Eddy Littler to remain as Chief Operating Officer ReViral Ltd., a cl...
ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&...
We have published hundreds of ReViral news stories on BioPortfolio along with dozens of ReViral Clinical Trials and PubMed Articles about ReViral for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ReViral Companies in our database. You can also find out about relevant ReViral Drugs and Medications on this site too.